Merck & Co Inc (MRK): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Merck ( MRK) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.7%. By the end of trading, Merck fell $0.71 (-1.4%) to $48.73 on average volume. Throughout the day, 24,527,149 shares of Merck exchanged hands as compared to its average daily volume of 17,874,600 shares. The stock ranged in price between $48.48-$49.73 after having opened the day at $49.02 as compared to the previous trading day's close of $49.44. Other companies within the Drugs industry that declined today were: Affymax ( AFFY), down 23.1%, Skystar Bio-Pharmaceutical Company ( SKBI), down 16.9%, Novogen ( NVGN), down 13.2% and Zogenix ( ZGNX), down 11.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $146.3 billion and is part of the health care sector. The company has a P/E ratio of 24.7, above the S&P 500 P/E ratio of 17.7. Shares are up 20.8% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Merck a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Savient Pharmaceuticals ( SVNT), down 28.4%, Rexahn Pharmaceuticals ( RNN), down 20.0%, Hemispherx Biopharma ( HEB), down 15.9% and Atossa Genetics ( ATOS), down 13.5% , were all gainers within the drugs industry with Warner Chilcott ( WCRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.